Product Description
Amitriptylinoxide is an organic tricyclic compound. Amitriptylinoxide has been used in trials studying Major Depression. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amitriptylinoxide)
Mechanisms of Action: NET Blocker,SERT Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HolsboerMaschmeyer NeuroChemie
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|